Covid 19 Research using Clinical Trials (Home Page)
Report for D044882: Glucose Metabolism Disorders NIH
(Synonyms: Glucose Metabolism, Glucose Metabolism Disorde, Glucose Metabolism Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1346 | Linagliptin 5 MG Wiki | 1.00 |
| drug2082 | Respiratory physiotherapy Wiki | 1.00 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008659 | Metabolic Diseases NIH | 1.00 |
| D004700 | Endocrine System Diseases NIH | 1.00 |
| D003924 | Diabetes Mellitus, Type 2 NIH | 0.41 |
| D003920 | Diabetes Mellitus, NIH | 0.32 |
| D012140 | Respiratory Tract Diseases NIH | 0.24 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000818 | Abnormality of the endocrine system HPO | 1.00 |
| HP:0005978 | Type II diabetes mellitus HPO | 0.41 |
| HP:0000819 | Diabetes mellitus HPO | 0.32 |
There is one clinical trial.
Clinical Trials
1 Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various effects on the immune system and several diseases, including lung diseases. This trial aims to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of COVID-19. The trial will be randomized without blinding, with one are treated by insulin only for glucose balance and the other by insulin and linagliptin. The trial will assess the effects of linagliptin on different measures of COVID-19 recovery.
NCT04371978 COVID 19 Coronavirus Diabetes Mellitus, Type 2 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Disease Endocrine System Diseases Dipeptidyl-Peptidase IV Inhibitors Linagliptin Severe Acute Respiratory Syndrome Coronavirus 2 Sars-CoV2 Hypoglycemic Agents Respiratory Tract Diseases Inc Incretins Hormones Drug: Linagliptin 5 MG MeSH:Coronaviru Coronavirus Infections Severe Acute Respiratory Syndrome Diabetes Mellitus Diabetes Mellitus, Type 2 Metabolic Diseases Glucose Metabolism Disorders Respiratory Tract Diseases Endocrine System Diseases
HPO:Abnormality of the endocrine system Diabetes mellitus Type II diabetes mellitus
Primary Outcomes
Description: Clinical change is defined as 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19: 0 - No clinical or virological evidence of infection; 1 - No limitation of activities; 2 - Limitation of activities; 3 - Hospitalized, no oxygen therapy; 4 - Oxygen by mask or nasal prongs; 5 - Non-invasive ventilation or high-flow oxygen; 6 - Intubation and mechanical ventilation; 7 - Ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation; 8 - Death.
Measure: Time to clinical change Time: 28 days
Secondary Outcomes
Measure: Percent of serious adverse events and premature discontinuation of treatment. Time: 28 days
Description: Percent of patients with a 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19.
Measure: Percent of patients with clinical improvement. Time: 28 days
Measure: Length of hospitalization. Time: 28 days
Measure: All-cause mortality. Time: 28 days
Measure: Percent of supplemental oxygen use. Time: 28 days
Measure: Supplemental oxygen-free days. Time: 28 days
Measure: Percent of mechanical ventilation use. Time: 28 days
Measure: Ventilator-free days. Time: 28 days
Measure: Percent of ICU admissions. Time: 28 days
Measure: ICU-free days. Time: 28 days
Measure: Percent of 50% decrease in C-reactive protein (CRP) levels Time: Up to 28 days
Measure: Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test. Time: 28 days
HPO Nodes
Primary Outcomes
Description: Clinical change is defined as 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19: 0 - No clinical or virological evidence of infection; 1 - No limitation of activities; 2 - Limitation of activities; 3 - Hospitalized, no oxygen therapy; 4 - Oxygen by mask or nasal prongs; 5 - Non-invasive ventilation or high-flow oxygen; 6 - Intubation and mechanical ventilation; 7 - Ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation; 8 - Death.
Measure: Time to clinical change Time: 28 daysSecondary Outcomes
Measure: Percent of serious adverse events and premature discontinuation of treatment. Time: 28 daysDescription: Percent of patients with a 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19.
Measure: Percent of patients with clinical improvement. Time: 28 daysMeasure: Length of hospitalization. Time: 28 days
Measure: All-cause mortality. Time: 28 days
Measure: Percent of supplemental oxygen use. Time: 28 days
Measure: Supplemental oxygen-free days. Time: 28 days
Measure: Percent of mechanical ventilation use. Time: 28 days
Measure: Ventilator-free days. Time: 28 days
Measure: Percent of ICU admissions. Time: 28 days
Measure: ICU-free days. Time: 28 days
Measure: Percent of 50% decrease in C-reactive protein (CRP) levels Time: Up to 28 days
Measure: Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test. Time: 28 days